INSERM, U1063, Stress oxydant et pathologies metaboliques, Universite d'Angers, Rue des Capucins, Angers, F-49100, France.
Curr Vasc Pharmacol. 2014 May;12(3):483-92. doi: 10.2174/1570161112666140423223148.
Heterogeneous in size (0.1-1 µm), microparticles are small membrane vesicles released from activated and/or apoptotic cells. Although described since 1967 by Wolf, it is only since the 1990's that microparticles have been considered as biomarkers as well as potential mediators of biological messages between cells by acting as paracrine and endocrine vectors. Detection of microparticles has been performed in biological fluids (blood, synovial fluid, saliva for instance) and some solid tissues but also from the culture medium. Levels of circulating microparticles are enhanced in a large number of pathological states including cardiovascular and metabolic disorders associated with insulin resistance and this has been linked to deleterious effects on cells from the vascular wall, mainly, endothelial cells. This review highlights the increasing impact of microparticles in major cardiovascular pathological situations associated with metabolic derangements.
微粒体大小不均(0.1-1 µm),是从激活和/或凋亡细胞中释放的小膜囊泡。虽然早在 1967 年就被 Wolf 描述过,但直到 20 世纪 90 年代,微粒体才被认为是生物标志物,也是细胞间生物信息的潜在介质,通过作为旁分泌和内分泌载体发挥作用。微粒体已在生物体液(例如血液、滑液、唾液)和一些实体组织中被检测到,也可从培养基中检测到。在包括心血管和代谢紊乱在内的大量病理状态下,循环微粒体的水平会升高,这些紊乱与胰岛素抵抗有关,这与对血管壁细胞(主要是内皮细胞)的有害影响有关。这篇综述强调了微粒体在与代谢紊乱相关的主要心血管病理情况下的日益重要的影响。